DNA Vaccines Suppress Angiogenesis and Protect Against Growth of Breast Cancer Metastases

Issue title: Immunology of Breast Cancer

Guest editors: Wei-Zen Weix and Diana Lopezy

Article type: Research Article

Authors: Mizutani, N. | Luo, Y. | Mizutani, M. | Reisfeld, R.A. | Xiang, R.

Affiliations: The Scripps Research Institute, 10550 N. Torrey Pines Rd., IMM13, La Jolla, CA. 92037, USA. Tel.: +1 858 784 8105; Fax: +1 858 784 2708; E-mail: reisfeld@scripps.edu; yluo@scripps.edu; nmizutani@scripps.edu; mmizutani@scripps.edu; rxiang@scripps.edu | [x] Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA | [y] Department of Microbiology and Immunology, University of Miami School of Medicine, Miami, FL 33136, USA

Abstract: Two novel oral DNA-based vaccines provide immune protection against breast cancer in mouse model systems. These vaccines are delivered by attenuated Salmonella typhimurium to secondary lymphoid organs and are directed against novel targets such as transcription factor Fos-related antigen 1 (Fra-1) and endoglin (CD105). Both vaccines elicit suppression of angiogenesis in the breast tumor vasculature and break peripheral tolerance by eliciting potent cell-mediated protective immunity against these tumor self-antigens resulting in effective suppression of breast tumor growth and metastasis.

DOI: 10.3233/BD-2004-20110

Journal: Breast Disease, vol. 20, no. 1, pp. 81-91, 2004